sFlt2-13

General Information


DRACP ID  DRACP04932

Peptide Name   sFlt2-13

Sequence  LVPLPKIKNSTFT

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic 

Disulfide/Other Bond  Native peptide

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C69H116N16O18

Absent amino acids  ACDEGHMQRWY

Common amino acids  KLPT

Mass  167199

Pl  10.81

Basic residues  2

Acidic residues  0

Hydrophobic residues  5

Net charge  2

Boman Index  -450

Hydrophobicity  18.46

Aliphatic Index  112.31

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 11311231

Title  A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor

Doi 10.1016/s0014-5793(01)02314-6

Year  2001

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.